[HTML][HTML] Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
BM Bordeau, JP Balthasar - Cancer biology & medicine, 2021 - ncbi.nlm.nih.gov
Despite the significant resources dedicated to the development of monoclonal antibody
(mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited …
(mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited …
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of
a wide range of solid tumors. The targeted nature of these biotherapeutics has improved …
a wide range of solid tumors. The targeted nature of these biotherapeutics has improved …
Biological impediments to monoclonal antibody–based cancer immunotherapy
J Christiansen, AK Rajasekaran - Molecular cancer therapeutics, 2004 - AACR
The ability of antibodies to exploit antigenic differences between normal and malignant
tissues and to exact a variety of antitumor responses offers significant advantages to …
tissues and to exact a variety of antitumor responses offers significant advantages to …
Monoclonal antibody dose determination and biodistribution into solid tumors
RA Beckman, R von Roemeling, AM Scott - Therapeutic Delivery, 2011 - Taylor & Francis
Monoclonal antibodies are increasingly being used as protein therapeutics for cancer. They
offer very specific binding to target molecules on the surface of cancer cells, relatively few …
offer very specific binding to target molecules on the surface of cancer cells, relatively few …
[HTML][HTML] Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors
KT Xenaki, S Oliveira… - Frontiers in …, 2017 - frontiersin.org
The use of antibody-based therapeutics has proven very promising for clinical applications
in cancer patients, with multiple examples of antibodies and antibody–drug conjugates …
in cancer patients, with multiple examples of antibodies and antibody–drug conjugates …
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells
Monoclonal antibodies (mAb) have become a mainstay in tumor therapy. Clinical responses
to mAb therapy, however, are far from optimal, with many patients presenting native or …
to mAb therapy, however, are far from optimal, with many patients presenting native or …
Overcoming biological barriers to improve solid tumor immunotherapy
Cancer immunotherapy has been at the forefront of therapeutic interventions for many
different tumor types over the last decade. While the discovery of immunotherapeutics …
different tumor types over the last decade. While the discovery of immunotherapeutics …
[CITATION][C] Penetration of tumor tissue by antibodies and other immunoproteins
TR Shockley, KE Lin, JA Nagy… - Annals of the New …, 1991 - Wiley Online Library
The advent of monoclonal antibody (MAb) techniques has led to an explosion of ideas, in
vitro and in vivo animal studies, and clinical trials aimed at evaluating the use of antibodies …
vitro and in vivo animal studies, and clinical trials aimed at evaluating the use of antibodies …
[CITATION][C] Tumor Physiology and Antibody Delivery1
RK Jain - The Present and Future Role of Monoclonal Antibodies …, 1989 - karger.com
The advent of hybridoma technology and genetic engineering has led to the design and
large-scale production of monoclonal antibodies (MAbs) and other biological …
large-scale production of monoclonal antibodies (MAbs) and other biological …
Barriers to antibody therapy in solid tumors, and their solutions
Y Matsumura - Cancer Science, 2021 - Wiley Online Library
Antibody drugs have become the mainstream of cancer treatment due to advances in cancer
biology and Ab engineering. However, several barriers to Ab therapy have also been …
biology and Ab engineering. However, several barriers to Ab therapy have also been …
Related searches
- solid tumors antibody uptake
- solid tumors clinical limitations
- solid tumors treatment efficacy
- solid tumors molecular imaging
- solid tumors targeted therapy
- biological impediments monoclonal antibody
- cancer immunotherapy monoclonal antibody
- monoclonal antibodies tumor accumulation
- solid tumors antibody therapy